Enlivex Therapeutics Ltd.

NASDAQ: ENLV · Real-Time Price · USD
1.82
0.04 (2.25%)
At close: Aug 15, 2025, 3:59 PM
1.91
4.95%
After-hours: Aug 15, 2025, 07:55 PM EDT

Enlivex Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
3.3M 813K 47.82M 11.2M
Short-Term Investments
20.2M 26.51M 299K 72.93M
Long-Term Investments
531K 308K 307K 3K
Other Long-Term Assets
10K 179K 105K 482K
Receivables
1.3M n/a n/a 1.09M
Inventory
n/a n/a 1.18M -12.2M
Other Current Assets
198K 5.11M n/a 1.2M
Total Current Assets
25.99M 33.76M 52.33M 86.44M
Property-Plant & Equipment
1.15M 2.58M 14.9M 8.22M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
1.69M 3.07M 15.31M 8.7M
Total Assets
27.69M 36.83M 67.64M 95.15M
Account Payables
811K 827K 1.95M 878K
Deferred Revenue
n/a n/a n/a n/a
Short-Term Debt
n/a n/a n/a n/a
Other Current Liabilities
1.55M 1.57M n/a n/a
Total Current Liabilities
3.8M 6.06M 6.61M 4.72M
Long-Term Debt
n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a n/a n/a
Total Long-Term Liabilities
299K 686K 4.19M 5.39M
Total Liabilities
4.1M 6.75M 10.8M 10.11M
Total Debt
534K 1.03M 4.85M 617K
Common Stock
2.69M 2.14M 2.12M 2.11M
Retained Earnings
-127.11M -112.09M -83.03M -51.97M
Comprehensive Income
1.1M 1.1M 1.1M 1.1M
Shareholders Equity
23.59M 30.08M 56.84M 85.04M
Total Investments
20.73M 26.82M 299K 72.93M